A5042148258- Parathyroid Disorders and Treatments
- Bone health and treatments
- Thyroid and Parathyroid Surgery
- Bone health and osteoporosis research
- Vitamin D Research Studies
- Thyroid Cancer Diagnosis and Treatment
- Genetic Syndromes and Imprinting
- Bone Metabolism and Diseases
- LGBTQ Health, Identity, and Policy
- Neuroendocrine Tumor Research Advances
- Bone and Joint Diseases
- Growth Hormone and Insulin-like Growth Factors
- Medical Imaging and Pathology Studies
- Congenital heart defects research
- Voice and Speech Disorders
- Diabetes and associated disorders
- Cancer Treatment and Pharmacology
- Bone and Dental Protein Studies
- Psoriasis: Treatment and Pathogenesis
- Parkinson's Disease and Spinal Disorders
- Airway Management and Intubation Techniques
- Metabolism, Diabetes, and Cancer
- Pancreatic and Hepatic Oncology Research
- Lipid metabolism and biosynthesis
- Vitamin C and Antioxidants Research
Lenox Hill Hospital
2018-2024
Danbury Hospital
2024
Northwell Health
2019-2022
Universidade de Pernambuco
2022
Mayo Clinic
2022
Hofstra University
2020-2022
Azienda Ospedaliera Universitaria Pisana
2022
Faculdade Frassinetti do Recife
2022
Columbia University
2010-2018
Columbia University Irving Medical Center
2015-2016
This report summarizes data on traditional and nontraditional manifestations of primary hyperparathyroidism (PHPT) that have been published since the last International Workshop PHPT.This subgroup was constituted by Steering Committee to address key questions related presentation PHPT. Consensus established at a closed meeting Expert Panel followed.Data from 5-year period between 2008 2013 were presented discussed determine whether they support changes in recommendations for surgery or...
Abstract Typically, in the milder form of primary hyperparathyroidism (PHPT), now seen most countries, bone density by dual-energy X-ray absorptiometry (DXA) and detailed analyses iliac crest biopsies histomorphometry micro–computed tomography (µCT) show detrimental effects cortical bone, whereas trabecular site (lumbar spine DXA) compartment (by biopsy) appear to be relatively well preserved. Despite these findings, fracture risk at both vertebral nonvertebral sites is increased PHPT....
Context:PTH may be an effective treatment option for hypoparathyroidism, but long-term data are not available.
Complaints from hypoparathyroid patients often reflect a reduction in quality of life (QOL), yet few data exist characterizing these complaints or the potential effects PTH therapy to ameliorate them. We tested hypothesis that PTH(1–84) improves QOL hypoparathyroidism. Fifty-four subjects received open-label recombinant human PTH(1–84). Before and during PTH(1–84), completed RAND 36-Item Health Survey, measure health-related covering 8 domains physical mental health. At baseline, scored...
Normocalcemic primary hyperparathyroidism is typically identified after referral to a specialty clinic. At diagnosis, patients demonstrate features seen in hypercalcemic hyperparathyroidism. hypoparathyroidism has been discovered hypocalcemia unmasked bisphosphonate administration. We hypothesized that screening unselected, nonreferral populations, such as The Osteoporotic Fractures Men (MrOS) study and Dallas Heart Study (DHS), would identify asymptomatic subjects with normocalcemic...
Human recombinant (rh)PTH(1–84) was recently approved for the treatment of refractory hypoparathyroidism, based upon a short-term phase 3 clinical trial. Long-term data are needed, because no time limit placed on period. We studied effect long-term rhPTH(1–84) in hypoparathyroidism up to 6 years. Prospective open-label study. Referral center. A total 33 subjects with hypoparathyroidism. initiated at starting dose 100 μg every other day Due availability new dosages during 6-year period study,...
In hypoparathyroidism, quality of life (QOL) is compromised as compared to normal subjects. We previously reported our results showing an association with recombinant human PTH(1-84) therapy in hypoparathyroidism and improvement QOL measures for 1 year.We tested the hypothesis that through 5 years would be associated continued measures.Sixty-nine hypoparathyroid subjects received open-label PTH(1-84). Before during therapy, completed RAND 36-Item Short Form (SF-36) Health Survey, a measure...
ABSTRACT In hypoparathyroidism, areal bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) is above average, and skeletal indices biopsy are abnormal. We used high-resolution peripheral quantitative computed tomography (HRpQCT) finite element analyses (FEA) to further investigate microstructure estimated strength. studied 60 hypoparathyroid subjects on conventional therapy using DXA, HRpQCT, FEA of the distal radius tibia compared with normative controls from Canadian...
Abstract Context Conventional treatment of hypoparathyroidism is associated with decreased renal function and increased bone mineral density (BMD). Objective To evaluate the effects 8 years recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] therapy on key biochemical densitometric indices. Design Prospective open-label trial. Setting Tertiary medical center. Participants Twenty-four subjects hypoparathyroidism. Intervention Treatment rhPTH(1-84) for years. Main Outcome Measures...
Hypercalcemia in ambulatory patients is occasionally caused by vitamin D toxicity.We report nine presenting to Columbia University Medical Center with hypercalcemia due a supplement from the Dominican Republic containing massive amounts of D.Case histories and laboratory evaluation (calcium, PTH, metabolites) are discussed context other published cases toxicity. The was analyzed HPLC quantitate A content.Nine presented (range, 10.8-17.2 mg/dl; normal, 8.4-9.8 mg/dl), suppressed PTH <3 11...